Standards of care and novel approaches in the management of glioblastoma multiforme
Explore this paper's citation graph
Summary
The standard treatment options for GBM are reviewed and the results obtained in clinical trials for promising novel approaches are evaluated, including the inhibition of angiogenesis, targeted approaches against molecular pathways, immunotherapies, and local treatment with low voltage electric fields.
- Type
- review
- Published
- 2014-01-01
- Cited by
- 132
- References
- 56
- Access
- Open access
- OpenAlex
- https://openalex.org/W2032940213
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:17795661
Keywords
Glioblastoma, Medicine, Standard of care, Clinical trial, Brain tumor
References
- Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study.
- Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
- Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
- Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)
- Bevacizumab does not increase the risk of remote relapse in malignant glioma
- Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.
- Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.
- Is Long-Term Survival in Glioblastoma Possible? Updated Results of the EORTC/NCIC Phase III Randomized Trial on Radiotherapy (RT) and Concomitant and Adjuvant Temozolomide (TMZ) versus RT Alone
- A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
- Expression of VEGF and its receptors in different brain tumors
- A survey of glioblastoma genomic amplifications and deletions
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
- A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas
- Cilengitide in Patients with Recurrent Glioblastoma: The Results of NABTC 03-02, a Phase II Trial with Measures of Treatment Delivery
- Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
- Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
- Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
- Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Cited by
- Co‐occurrence of astrocytoma and astroblastoma: Case report and literature review
- MicroRNA-584 functions as a tumor suppressor and targets PTTG1IP in glioma.
- Combination of the multipotent mesenchymal stromal cell transplantation with administration of temozolomide increases survival of rats with experimental glioblastoma.
- Xyloketal B Suppresses Glioblastoma Cell Proliferation and Migration in Vitro through Inhibiting TRPM7-Regulated PI3K/Akt and MEK/ERK Signaling Pathways
- PCAF-mediated Akt1 acetylation enhances the proliferation of human glioblastoma cells
- Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy – Detecting Illusive Disease, Defining Response
- Recent news in the glioblastoma research
- Drug and cell encapsulation: alternative delivery options for the treatment of malignant brain tumors.
- miR-101 reverses hypomethylation of the PRDM16 promoter to disrupt mitochondrial function in astrocytoma cells
- Open Peer Review
- An assay to measure poly(ADP ribose) glycohydrolase (PARG) activity in cells
- Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas
- miR-503 inhibits cell proliferation and invasion in glioma by targeting L1CAM.
- NOS Expression and NO Function in Glioma and Implications for Patient Therapies
- Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone
- Intracranial AAV-IFNβ gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model
- Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis
- Recurrent Malignant Gliomas: Treatment Options and Their Effect on Patient's Quality of Life.
- Evaluation of the therapeutic potential of red clover extract and red grape seed extract on human adult malignant brain tumours in vitro
- Novel Therapeutic Approaches to Induce Autophagy in Brain Cancer
Related papers
- 2. Glioblastoma再発に対しTemozolomideを使用した１例(第35回群馬脳腫瘍研究会)
- 12-Cycle of Temozolomide Treatment is not Superior To 6-Cycle of Treatment in Glioblastoma Multiforme
- RTHP-09. PROGRESSION AND PSEUDOPROGRESSION OF GLIOBLASTOMA MULTIFORME IN THE TEMOZOLOMIDE ERA
- P01.110 Elderly patients >65years of age with newly diagnosed Glioblastoma multiforme gain life time from treatment with Tumor Treating Fields and Temozolomide
- EP-1204: Limited margin radiotherapy and temozolomide for glioblastoma multiforme: pattern of failure
- EXTH-25. EFFECTS OF TUMOR TREATING FIELDS (TTFIELDS) AND TEMOZOLOMIDE IN MGMT EXPRESSING AND NON-EXPRESSING PATIENT-DERIVED GLIOBLASTOMA CELLS
- Pharmacoeconomic Analysis of Intravenous Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Russia
- PO-0659 RADIOTHERAPY AND TEMOZOLOMIDE IN ELDERLY PATIENTS WITH GLIOBLASTOMA
- Utility of Dynamic Contrast-Enhanced (DCE) MRI in Predicting Prognosis of Enhancing Lesions Persisting after Completion of Adjuvant Temozolomide in Glioblastoma Patients
- Recurrence Patterns of Glioblastoma in the Era of Temozolomide